

# Magnus P Ekström

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5854516/publications.pdf>

Version: 2024-02-01

166  
papers

3,817  
citations

147801

31  
h-index

161849

54  
g-index

169  
all docs

169  
docs citations

169  
times ranked

3155  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overuse of short-acting $\beta_2$ -agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. <i>European Respiratory Journal</i> , 2020, 55, 1901872.	6.7	274
2	Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. <i>BMJ</i> , The, 2014, 348, g445-g445.	6.0	240
3	Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. <i>European Respiratory Journal</i> , 2017, 49, 1602277.	6.7	215
4	Effects of Opioids on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1079-1092.	3.2	163
5	Effects of Cardiovascular Drugs on Mortality in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 715-720.	5.6	133
6	Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e121-e141.	5.6	133
7	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. <i>Clinical Epidemiology</i> , 2021, Volume 13, 21-41.	3.0	111
8	One evidence base; three stories: do opioids relieve chronic breathlessness?. <i>Thorax</i> , 2018, 73, 88-90.	5.6	98
9	End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. <i>Thorax</i> , 2016, 71, 510-516.	5.6	88
10	COVID-19: guidance on palliative care from a European Respiratory Society international task force. <i>European Respiratory Journal</i> , 2020, 56, 2002583.	6.7	69
11	The management of chronic breathlessness in patients with advanced and terminal illness. <i>BMJ</i> , The, 2015, 349, g7617-g7617.	6.0	66
12	Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2181-2190.	5.7	60
13	Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study. <i>BMJ Open</i> , 2014, 4, e004018.	1.9	55
14	Is chronic breathlessness less recognised and treated compared with chronic pain? A case-based randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 52, 1800887.	6.7	51
15	Comorbidity and Sex-Related Differences in Mortality in Oxygen-Dependent Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2012, 7, e35806.	2.5	50
16	Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis: Figure 1. <i>Thorax</i> , 2015, 70, 492-494.	5.6	49
17	Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: a population-based prospective study. <i>Respiratory Research</i> , 2014, 15, 30.	3.6	48
18	Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. <i>European Respiratory Journal</i> , 2018, 52, 1801278.	6.7	47

#	ARTICLE	IF	CITATIONS
19	Occupational risk factors for idiopathic pulmonary fibrosis in Southern Europe: a case-control study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 75.	2.0	43
20	Trends in Cause-Specific Mortality in Oxygen-dependent Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1032-1036.	5.6	42
21	Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. <i>The Cochrane Library</i> , 2017, 2017, CD006429.	2.8	42
22	Absolute values of lung function explain the sex difference in breathlessness in the general population. <i>European Respiratory Journal</i> , 2017, 49, 1602047.	6.7	41
23	Factors influencing adherence to continuous positive airway pressure treatment in obstructive sleep apnea and mortality associated with treatment failure – a national registry-based cohort study. <i>Sleep Medicine</i> , 2018, 51, 85-91.	1.6	41
24	Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. <i>European Respiratory Journal</i> , 2019, 53, 1801270.	6.7	41
25	Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines. <i>ESMO Open</i> , 2020, 5, e001038.	4.5	41
26	Breathlessness, Anxiety, Depression, and Function – The BAD-F Study: A Cross-Sectional and Population Prevalence Study in Adults. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 197-205.e2.	1.2	40
27	Persistent disabling breathlessness in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2016, Volume 11, 2805-2812.	2.3	38
28	Prescription of opioids for breathlessness in end-stage COPD: a national population-based study. <i>International Journal of COPD</i> , 2016, Volume 11, 2651-2657.	2.3	37
29	Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits. <i>European Respiratory Journal</i> , 2017, 50, 1700198.	6.7	36
30	Age- and gender-specific upper limits and reference equations for workload-indexed systolic blood pressure response during bicycle ergometry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1360-1369.	1.8	36
31	Absolute lung size and the sex difference in breathlessness in the general population. <i>PLoS ONE</i> , 2018, 13, e0190876.	2.5	35
32	Breathlessness in Elderly Adults During the Last Year of Life Sufficient to Restrict Activity: Prevalence, Pattern, and Associated Factors. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 73-80.	2.6	33
33	Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?. <i>BMJ Open</i> , 2015, 5, e006818-e006818.	1.9	32
34	The need to research refractory breathlessness. <i>European Respiratory Journal</i> , 2016, 47, 342-343.	6.7	32
35	End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. <i>European Respiratory Journal</i> , 2015, 46, 1190-1193.	6.7	31
36	Breathlessness measurement should be standardised for the level of exertion. <i>European Respiratory Journal</i> , 2018, 51, 1800486.	6.7	31

#	ARTICLE	IF	CITATIONS
37	Minimal Clinically Important Differences and Feasibility of Dyspnea-12 and the Multidimensional Dyspnea Profile in Cardiorespiratory Disease. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 968-975.e1.	1.2	31
38	Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden. <i>International Journal of COPD</i> , 2016, Volume 11, 1663-1669.	2.3	30
39	A nationwide structure for valid long-term oxygen therapy: 29-year prospective data in Sweden. <i>International Journal of COPD</i> , 2017, Volume 12, 3159-3169.	2.3	30
40	The trajectory of functional decline over the last 4 months of life in a palliative care population: A prospective, consecutive cohort study. <i>Palliative Medicine</i> , 2019, 33, 693-703.	3.1	30
41	Controlled-Release Oxycodone vs. Placebo in the Treatment of Chronic Breathlessness—A Multisite Randomized Placebo Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 581-589.	1.2	30
42	Long-Term Oxygen Therapy 24 vs 15 h/day and Mortality in Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2016, 11, e0163293.	2.5	30
43	Breathlessness During the Last Week of Life in Palliative Care: An Australian Prospective, Longitudinal Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 816-823.	1.2	27
44	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. <i>BMJ Open</i> , 2017, 7, e018100.	1.9	27
45	Increased Relative Mortality in Women With Severe Oxygen-Dependent COPD. <i>Chest</i> , 2010, 137, 31-36.	0.8	25
46	Underlying contributing conditions to breathlessness among middle-aged individuals in the general population: a cross-sectional study. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000643.	3.0	25
47	Validation of the Swedish Multidimensional Dyspnea Profile (MDP) in outpatients with cardiorespiratory disease. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000381.	3.0	24
48	Clinical Usefulness of Long-Term Oxygen Therapy in Adults. <i>New England Journal of Medicine</i> , 2016, 375, 1683-1684.	27.0	23
49	Who experiences higher and increasing breathlessness in advanced cancer? The longitudinal EPCCS Study. <i>Supportive Care in Cancer</i> , 2016, 24, 3803-3811.	2.2	22
50	Patient reported outcome measures in chronic obstructive pulmonary disease: Which to use?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 351-362.	2.5	21
51	The association of body mass index, weight gain and central obesity with activity-related breathlessness: the Swedish Cardiopulmonary Bioimage Study. <i>Thorax</i> , 2019, 74, 958-964.	5.6	21
52	Breathlessness and incidence of COPD, cardiac events and all-cause mortality: A 44-year follow-up from middle age throughout life. <i>PLoS ONE</i> , 2019, 14, e0214083.	2.5	21
53	How to Assess Breathlessness in Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2021, Volume 16, 1581-1598.	2.3	21
54	The independent association of overweight and obesity with breathlessness in adults: a cross-sectional, population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700558.	6.7	20

#	ARTICLE	IF	CITATIONS
55	Breathlessness and sexual activity in older adults: the Australian Longitudinal Study of Ageing. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 20.	2.6	20
56	Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000418.	3.0	20
57	Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis: A population-based longitudinal study. <i>Respirology</i> , 2016, 21, 705-711.	2.3	19
58	Why treatment efficacy on breathlessness in laboratory but not daily life trials? The importance of standardized exertion. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 179-183.	1.3	18
59	Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness. <i>European Respiratory Journal</i> , 2020, 56, 1902202.	6.7	18
60	Extended-Release Morphine for Chronic Breathlessness in Pulmonary Arterial Hypertension—A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 483-492.	1.2	17
61	Survival Benefit of Lung Transplantation for Chronic Obstructive Pulmonary Disease in Sweden. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1930-1935.	1.3	16
62	Socioeconomic Factors and Adherence to CPAP. <i>Chest</i> , 2021, 160, 1481-1491.	0.8	16
63	The risk of burn injury during long-term oxygen therapy: a 17-year longitudinal national study in Sweden. <i>International Journal of COPD</i> , 2015, 10, 2479.	2.3	15
64	Swedish translation and linguistic validation of the multidimensional dyspnoea profile. <i>European Clinical Respiratory Journal</i> , 2016, 3, 32665.	1.5	15
65	Dyspnoea-12 and Multidimensional Dyspnea Profile: Systematic Review of Use and Properties. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e75-e87.	1.2	15
66	Agreement Between Breathlessness Severity and Unpleasantness in People With Chronic Breathlessness: A Longitudinal Clinical Study. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 715-723.e5.	1.2	14
67	Validation of the Swedevox registry of continuous positive airway pressure, long-term mechanical ventilator and long-term oxygen therapy. <i>ERJ Open Research</i> , 2021, 7, 00340-2020.	2.6	14
68	Dyspnoea-12: a translation and linguistic validation study in a Swedish setting. <i>BMJ Open</i> , 2017, 7, e014490.	1.9	13
69	Validation of the Dyspnea Exertion Scale of Breathlessness in People With Life-Limiting Illness. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 430-435.e2.	1.2	13
70	Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2...weeks and 6...months: follow-up of a longitudinal clinical study. <i>European Respiratory Journal</i> , 2021, 57, 2002823.	6.7	13
71	Outcome measurement of refractory breathlessness. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 238-243.	1.3	12
72	Risk of cancer after lung transplantation for COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 2841-2847.	2.3	12

#	ARTICLE	IF	CITATIONS
73	Activities Forgone because of Chronic Breathlessness: A Cross-Sectional Population Prevalence Study. <i>Palliative Medicine Reports</i> , 2020, 1, 166-170.	0.9	12
74	Risk of Rehospitalization and Death in Patients Hospitalized Due to Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1960-1968.e4.	3.8	12
75	Health service utilisation associated with chronic breathlessness: random population sample. <i>ERJ Open Research</i> , 2021, 7, 00415-2021.	2.6	12
76	Course of Disease In patients reported to the Swedish CPAP Oxygen and Ventilator Registry (DISCOVERY) with population-based controls. <i>BMJ Open</i> , 2020, 10, e040396.	1.9	12
77	Underlying conditions contributing to breathlessness in the population. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 219-225.	1.3	12
78	Risk factors for developing hypoxic respiratory failure in COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 2095-2100.	2.3	11
79	Burn injury during long-term oxygen therapy in Denmark and Sweden: the potential role of smoking. <i>International Journal of COPD</i> , 2017, Volume 12, 193-197.	2.3	11
80	Missed opportunity? Worsening breathlessness as a harbinger of death: a cohort study. <i>European Respiratory Journal</i> , 2018, 52, 1800684.	6.7	11
81	Severe alpha <sub>1</sub> -antitrypsin deficiency increases the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1519-1525.	3.8	11
82	Prevalence of Sudden Death in Palliative Care: Data From the Australian Palliative Care Outcomes Collaboration. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 221-227.	1.2	10
83	Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward. <i>International Journal of COPD</i> , 2018, Volume 13, 231-235.	2.3	10
84	Calculated arterial blood gas values from a venous sample and pulse oximetry: Clinical validation. <i>PLoS ONE</i> , 2019, 14, e0215413.	2.5	10
85	Long-term follow-up of patients undergoing standardized bicycle exercise stress testing: new recommendations for grading of exercise capacity are clinically relevant. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 83-90.	1.2	10
86	Quality of Life Changes With Duration of Chronic Breathlessness: A Random Sample of Community-Dwelling People. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 818-827.e4.	1.2	10
87	Spirometric Volumes and Breathlessness across Levels of Airflow Limitation: The COPD Gene Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 678-681.	5.6	9
88	Registry-based randomized controlled trial of treatment and Duration and mortality in long-term Oxygen therapy (REDOX) study protocol. <i>BMC Pulmonary Medicine</i> , 2019, 19, 50.	2.0	9
89	Management and Risk of Mortality in Patients Hospitalised Due to a First Severe COPD Exacerbation. <i>International Journal of COPD</i> , 2020, Volume 15, 2673-2682.	2.3	9
90	No excess harms from sustained-release morphine: a randomised placebo-controlled trial in chronic breathlessness. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, 421-428.	1.6	9

#	ARTICLE	IF	CITATIONS
91	A practical measurement of thoracic sarcopenia: correlation with clinical parameters and outcomes in advanced lung cancer. ERJ Open Research, 2016, 2, 00085-2015.	2.6	8
92	Low agreement between mMRC rated by patients and clinicians: implications for practice. European Respiratory Journal, 2019, 54, 1901517.	6.7	8
93	Effectiveness trials: critical data to help understand how respiratory medicines really work?. European Clinical Respiratory Journal, 2019, 6, 1565804.	1.5	8
94	Differences between experienced and recalled breathlessness. Current Opinion in Supportive and Palliative Care, 2019, Publish Ahead of Print, 161-166.	1.3	8
95	Peak exercise SBP and future risk of cardiovascular disease and mortality. Journal of Hypertension, 2022, 40, 300-309.	0.5	8
96	Cancer risk in severe alpha-1-antitrypsin deficiency. European Respiratory Journal, 2022, 60, 2103200.	6.7	8
97	Prevalence and severity of differing dimensions of breathlessness among elderly males in the population. ERJ Open Research, 2022, 8, 00553-2021.	2.6	8
98	Comparing recalled versus experienced symptoms of breathlessness ratings: An ecological assessment study using mobile phone technology. Respiriology, 2022, 27, 874-881.	2.3	8
99	Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). Evidence-Based Medicine, 2015, 20, 39-39.	0.6	7
100	Job titles classified into socioeconomic and occupational groups identify subjects with increased risk for respiratory symptoms independent of occupational exposure to vapour, gas, dust, or fumes. European Clinical Respiratory Journal, 2018, 5, 1468715.	1.5	7
101	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. BMJ Open Respiratory Research, 2019, 6, e000370.	3.0	7
102	Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy – The population-based DISCOVERY study. Respiratory Medicine, 2021, 189, 106659.	2.9	7
103	Lower workforce participation is associated with more severe persisting breathlessness. BMC Pulmonary Medicine, 2022, 22, 93.	2.0	7
104	Persisting breathlessness and activities reduced or ceased: a population study in older men. BMJ Open Respiratory Research, 2022, 9, e001168.	3.0	7
105	Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status. International Journal of COPD, 2017, Volume 12, 3281-3287.	2.3	6
106	Chronic breathlessness: re-thinking the symptom. European Respiratory Journal, 2018, 51, 1800340.	6.7	6
107	<p>Patient registries for home oxygen research and evaluation</p>. International Journal of COPD, 2019, Volume 14, 1299-1304.	2.3	6
108	Isolating peripheral effects of endogenous opioids in modulating exertional breathlessness in people with moderate or severe COPD: a randomised controlled trial. ERJ Open Research, 2019, 5, 00153-2019.	2.6	6

#	ARTICLE	IF	CITATIONS
109	A common model for the breathlessness experience across cardiorespiratory disease. ERJ Open Research, 2021, 7, 00818-2020.	2.6	6
110	Sudden Death in Palliative Care. Journal of Pain and Symptom Management, 2015, 50, e1-e2.	1.2	5
111	Special diets are common among preschool children aged one to five years in south-east Sweden according to a population-based cross-sectional survey. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 634-638.	1.5	5
112	Chronic breathlessness: re-thinking the symptom. European Respiratory Journal, 2018, 51, 1702326.	6.7	5
113	Analysing data in palliative care trials. BMJ: British Medical Journal, 2018, 362, k2943.	2.3	5
114	Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population. International Journal of COPD, 2020, Volume 15, 1245-1252.	2.3	5
115	A phase III, multi-site, randomised, double blind, placebo controlled parallel arm study of daily extended release (ER) morphine for chronic breathlessness. , 2016, , .		5
116	No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial. ERJ Open Research, 2020, 6, 00342-2020.	2.6	5
117	Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnoea treatment. European Respiratory Journal, 2022, 59, 2200237.	6.7	5
118	Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. European Respiratory Journal, 2017, 50, 1701297.	6.7	4
119	Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study. ERJ Open Research, 2020, 6, 00299-2019.	2.6	4
120	Effect of the trajectory of exertional breathlessness on symptom recall and anticipation: A randomized controlled trial. PLoS ONE, 2020, 15, e0238937.	2.5	4
121	Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). Journal of Pain and Symptom Management, 2020, 60, 346-354.e2.	1.2	4
122	Typical angina during exercise stress testing improves the prediction of future acute coronary syndrome. Clinical Physiology and Functional Imaging, 2021, 41, 281-291.	1.2	4
123	Breathlessness across generations: results from the RHINESSA generation study. Thorax, 2022, 77, 172-177.	5.6	4
124	Indications and patterns of use of benzodiazepines and opioids in severe interstitial lung disease: a population-based longitudinal study. ERJ Open Research, 2021, 7, 00716-2020.	2.6	4
125	Breathlessness dimensions association with physical and mental quality of life: the population based VASCOL study of elderly men. BMJ Open Respiratory Research, 2021, 8, e000990.	3.0	4
126	COVID-19 and Risk of Oxygen-Dependent Chronic Respiratory Failure: A National Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 506-509.	5.6	4



#	ARTICLE	IF	CITATIONS
127	Exploring the most important factors related to self-perceived health among older men in Sweden: a cross-sectional study using machine learning. <i>BMJ Open</i> , 2022, 12, e061242.	1.9	4
128	The rise and fall of COPD mortality. <i>Lancet Respiratory Medicine</i> , 2014, 2, 4-6.	10.7	3
129	Opioids in chronic obstructive pulmonary disease: the whole picture using all available evidence. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 795-796.	2.4	3
130	Conference presentation in palliative medicine: predictors of subsequent publication. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 73-77.	1.6	3
131	Predicting the rate of oxygen consumption during the 3-minute constant-rate stair stepping and shuttle tests in people with COPD. <i>Journal of Thoracic Disease</i> , 2020, 12, 2489-2498.	1.4	3
132	Agreement of the modified Medical Research Council and New York Heart Association scales for assessing the impact of self-rated breathlessness in cardiopulmonary disease. <i>ERJ Open Research</i> , 2022, 8, 00460-2021.	2.6	3
133	Paediatric reference values for the work rate-indexed systolic blood pressure response during exercise. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e283-e285.	1.8	3
134	Validation of the Dyspnoea-12 and Multidimensional Dyspnea profile among older Swedish men in the population. <i>BMC Geriatrics</i> , 2022, 22, .	2.7	3
135	Adverse Effects, Smoking, Alcohol Consumption, and Quality of Life during Long-Term Oxygen Therapy: A Nationwide Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1677-1686.	3.2	3
136	Prognostic implications of structural heart disease and premature ventricular contractions in recovery of exercise. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
137	Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. <i>European Respiratory Journal</i> , 2017, 49, 1602311.	6.7	2
138	Overdosing on immediate-release morphine solution has predictable adverse effects. <i>European Respiratory Journal</i> , 2017, 50, 1701091.	6.7	2
139	Palliative oxygen for chronic breathlessness: what new evidence?. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 159-164.	1.3	2
140	The strength of evidence: low dose morphine for chronic breathlessness. <i>Internal Medicine Journal</i> , 2018, 48, 102-103.	0.8	2
141	Daily duration of long-term oxygen therapy and risk of hospitalization in oxygen-dependent COPD patients. <i>International Journal of COPD</i> , 2018, Volume 13, 2623-2628.	2.3	2
142	Symptom patterns in populations. , 0, , 70-84.		2
143	Hypercapnia in Advanced Chronic Obstructive Pulmonary Disease: A Secondary Analysis of the National Emphysema Treatment Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2020, 7, 336-345.	0.7	2
144	What can we learn about breathlessness from population-based and administrative health data?. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 223-227.	1.3	1

#	ARTICLE	IF	CITATIONS
145	Antithrombotic treatment and risk of complications after head and neck full thickness skin graft surgery. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2018, 52, 333-337.	0.8	1
146	Editorial: Respiratory problems. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 155-156.	1.3	1
147	Breathing problems in focus. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, Publish Ahead of Print, 197-198.	1.3	1
148	Feasibility of completing Multidimensional Dyspnea Profile and Dyspnea-12 over the telephone in patients with oxygen-dependent disease. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001027.	3.0	1
149	Socioeconomic factors and adherence to Continuous Positive Airway Pressure - a population-based cohort study. , 2020, , .		1
150	Impact of covid-19 on long-term oxygen therapy 2020: A nationwide study in Sweden. <i>PLoS ONE</i> , 2022, 17, e0266367.	2.5	1
151	Cancer risk in severe alpha-1 antitrypsin deficiency: the importance of early identification. <i>European Respiratory Journal</i> , 2022, 60, 2200846.	6.7	1
152	Further Need for Evidence in Long-Term Oxygen Therapy. <i>Annals of the American Thoracic Society</i> , 2018, 15, 511-512.	3.2	0
153	Non-invasive positive pressure ventilation should be considered in patients with COPD and persistent hypercapnia at least 2 weeks after resolution of acute respiratory failure. <i>Evidence-based Nursing</i> , 2018, 21, 12-12.	0.2	0
154	Statistical compared to clinical significance and the risk of misattribution. <i>European Respiratory Journal</i> , 2018, 52, 1801723.	6.7	0
155	Breathlessness Isn't Cool, But Its Treatment Can Be. <i>Chest</i> , 2020, 157, 1401-1402.	0.8	0
156	Fan therapy is a treatment option for relieving of chronic breathlessness. <i>Evidence-based Nursing</i> , 2020, 23, 73-73.	0.2	0
157	Life's a gas: saturation should not be used for prescription of long-term oxygen therapy. <i>ERJ Open Research</i> , 2021, 7, 00495-2021.	2.6	0
158	Management of Respiratory Symptoms in People with Cancer. , 2018, , 217-229.		0
159	Condom use: why not?. <i>The National Medical Journal of India</i> , 2006, 19, 172.	0.3	0
160	Minimally clinically important improvements (MCII) and worsening (MCIW) in symptoms. <i>Journal of Pain and Symptom Management</i> , 2022, , .	1.2	0
161	Title is missing!. , 2020, 15, e0238937.		0
162	Title is missing!. , 2020, 15, e0238937.		0

#	ARTICLE	IF	CITATIONS
163	Title is missing!. , 2020, 15, e0238937.		0
164	Title is missing!. , 2020, 15, e0238937.		0
165	Title is missing!.. , 2020, 15, e0238937.		0
166	Title is missing!.. , 2020, 15, e0238937.		0